Search Videos and More
News
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.
News
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 38 of its researchers have been named to the Highly Cited Researchers list of 2025, released by the Institute for Scientific Information at Clarivate.
News
Dana-Farber Research Points to Potential Gene Therapy Improvements
Viruses aren’t thought of as living beings. Rather, they are collections of genetic instructions that hijack the replication machinery of living cells to perpetuate themselves.
News
Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally
Cancer can make its way through the body by shapeshifting through even the narrowest places, like a skilled driver navigating traffic. It has a sly way of adapting to its environment by finding detours around every blockade clinicians place in its path.
News
Three Ways Research Could Improve Pancreatic Cancer Treatment
Pancreatic cancer has long been difficult to detect and treat. Dana-Farber experts in the Hale Family Center for Pancreatic Cancer Research, however, are working to change that with research efforts in three key areas that are poised to advance early detection, early intervention, and treatment of the disease.
News
CD123 Targeted Therapies
CD123 is the alpha subunit of the interleukin 3 (IL-3) receptor. It pairs with a beta subunit, CD131, to transmit cytokine signals from the outside to inside of several types of immune and hematopoietic cells. CD123 is highly expressed on the cell surface of several blood cancers.
News
Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3
Venetoclax is an oral selective BCL2 inhibitor, which can restore apoptotic activation in leukemia cells that are dependent on this dysregulated pathway, and in combination with azacitidine (Aza/Ven), is an approved and common frontline therapy for patients with acute myeloid leukemia (AML).
News
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A new and potentially broadly applicable class of anti-leukemic agents has arrived on the scene due to preclinical work done in the laboratory of Scott Armstrong, MD, PhD, of Dana-Farber Cancer Institute in collaboration with members of the Adult Leukemia Program within Medical Oncology at Dana-Farber led by Richard Stone, MD, Chief of Staff.
News
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer
Jessica St. Laurent, MD, was sure something had gone wrong. The results of an experiment she’d run showed that the cancer cells she was studying had abnormally high levels of a specific collection of proteins of interest to her team.
News
Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments
Evaluating new medical therapies in people through a rigorous, systematic process, known as a clinical trial, is the pinnacle of clinical research and the primary mechanism through which novel treatments are proven safe and effective in cancer — or any other disease.
News
New Research Sheds Light on Why Tamoxifen May Lead to Higher Risk of Uterine Cancer
Since its introduction in the 1970s, tamoxifen has significantly improved survival rates for millions of patients with estrogen receptor–positive breast cancer.
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.